---
title: "Haisco grants AirNexis global rights to HSK39004 drug in deal exceeding USD 1 billion, targeting COPD market."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/272267678.md"
description: "A dual-target therapy known as HSK39004 is set to enter the competitive global market for Chronic Obstructive Pulmonary Disease (COPD) treatment. This innovative product signifies a focus on international capabilities and advancement. The announcement was made by Haisco Pharmaceutical Group Co., Ltd. on January 9, 2026. The company, identified by Ticker Code 002653, aims to make a significant impact in the field, showcasing their dedication to addressing respiratory issues on a global scale."
datetime: "2026-01-12T12:05:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/272267678.md)
  - [en](https://longbridge.com/en/news/272267678.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/272267678.md)
---

# Haisco grants AirNexis global rights to HSK39004 drug in deal exceeding USD 1 billion, targeting COPD market.

A dual-target therapy known as HSK39004 is set to enter the competitive global market for Chronic Obstructive Pulmonary Disease (COPD) treatment. This innovative product signifies a focus on international capabilities and advancement. The announcement was made by Haisco Pharmaceutical Group Co., Ltd. on January 9, 2026. The company, identified by Ticker Code 002653, aims to make a significant impact in the field, showcasing their dedication to addressing respiratory issues on a global scale.

### Related Stocks

- [002653.CN](https://longbridge.com/en/quote/002653.CN.md)

## Related News & Research

- [Apnimed's sleep apnea pill meets main goal in late-stage study](https://longbridge.com/en/news/286785038.md)
- [US working with small biotech firm on experimental Ebola treatment, Bloomberg News reports](https://longbridge.com/en/news/287108072.md)
- [Bergman: ‘The time is now’ to push for breakthroughs in psychedelic treatments](https://longbridge.com/en/news/286946328.md)
- [Sanofi says rare lung disease drug outperforms standard care in trial](https://longbridge.com/en/news/286810610.md)
- [Lupin bets big on India's GLP-1 market & respiratory drugs](https://longbridge.com/en/news/287021542.md)